Bouzini Ghizlan, Amzerin Mounia, Mahdi Zaynab, Sammoud Karima, Chahbar Abdelaziz, Najdi Adil, El M'rabet Fatima Zahra
Life and Health Science Laboratory, Faculty of Medicine and Pharmacy of Tangier, Center for Doctoral Studies in Sciences and Techniques and Medical Sciences (CED-STSM), Abdelmalek Essaadi University (UAE), Tangier, Morocco.
Oncology Center of the Mohammed VI University Hospital of Tangier, Faculty of Medicine and Pharmacy of Tangier, Abdelmalek Essaadi University (UAE), Tangier, Morocco.
Cancer Manag Res. 2025 Apr 21;17:851-861. doi: 10.2147/CMAR.S514238. eCollection 2025.
In Morocco, AMO-Tadamon is a basic mandatory health insurance scheme designed to ensure right to health for all. Implementation of this reform is advantageous for access to healthcare services. However, its impact on continuity of care needs to be assessed. In this study, we aimed to evaluate its impact on continuity of care for breast cancer patients at the Oncology Center of CHU Mohammed VI-Tangier between September 2022 and September 2023.
This was a mixed longitudinal cohort study. Follow-up information was collected over 13 months. December 1, 2022 was the index-event. Continuity of care was measured using "Bice-Boxerman Continuity of Care Index" and "Usual Provider Continuity" over three chronological sequences.
RESULTS/DISCUSSION: We recorded 74 cases in total, 16/74 were lost to follow-up (21.6%). Significant association (p=0.001; CI (0.01-0.04)) was observed between AMO-Tadamon generalization and continuity of care in our patients. For both indicators (UPC and COCI), mean continuity of care scores ranged from 0.25 to 0.75 over the three reference periods. This indicates a moderate overall continuity of care. During the first 4 months of this reform, significant positive associations were found between Therapy postponement and its implementation (p=0.003; CI (0.01--0.04)). Moreover, access to expensive drugs was significantly higher in the postgeneralization period (p=0.027; CI (0.01-0.04)).
Our study suggests a negative impact of this reform on patient care during the period of its generalization and a positive effect on access to expensive drugs after its generalization. A long-term follow-up study is planned. This will assess the impact of this reform on survival.
在摩洛哥,“AMO - 互助”是一项基本的强制性医疗保险计划,旨在确保所有人的健康权。这项改革的实施有利于获得医疗服务。然而,其对医疗连续性的影响需要评估。在本研究中,我们旨在评估2022年9月至2023年9月期间,该计划对穆罕默德六世 - 丹吉尔大学医院肿瘤中心乳腺癌患者医疗连续性的影响。
这是一项混合纵向队列研究。随访信息收集了13个月。2022年12月1日为索引事件。通过三个时间顺序序列,使用“比塞 - 博克斯曼医疗连续性指数”和“常规医疗服务提供者连续性”来衡量医疗连续性。
结果/讨论:我们总共记录了74例病例,其中16/74失访(21.6%)。在我们的患者中,观察到“AMO - 互助”普及与医疗连续性之间存在显著关联(p = 0.001;CI(0.01 - 0.04))。对于两个指标(UPC和COCI),在三个参考期内,医疗连续性平均得分在0.25至0.75之间。这表明总体医疗连续性中等。在这项改革的前4个月,治疗推迟与其实施之间存在显著的正相关(p = 0.003;CI(0.01 - 0.04))。此外,在普及期后,获得昂贵药物的机会显著更高(p = 0.027;CI(0.01 - 0.04))。
我们的研究表明,这项改革在普及期间对患者护理有负面影响,而在普及后对获得昂贵药物有积极影响。计划进行长期随访研究。这将评估这项改革对生存的影响。